Vivos Therapeutics (VVOS) Gross Profit (2020 - 2026)

Vivos Therapeutics (VVOS) has 7 years of Gross Profit data on file, last reported at $3.1 million in Q1 2026.

• On a quarterly basis, Gross Profit rose 102.72% year-over-year to $3.1 million in Q1 2026; TTM through Mar 2026 was $12.1 million, a 40.78% increase from a year earlier, with the FY2025 full-year figure at $10.5 million, up 16.89% from the prior year.
• Gross Profit for Q1 2026 stood at $3.1 million, up from $3.0 million in the prior quarter.
• Over the last five years, Gross Profit for VVOS reached as high as $3.9 million in Q3 2025 and fell as low as $1.5 million in Q1 2025.
• Historically, Gross Profit has averaged $2.4 million across 5 years, with a median of $2.3 million in 2023.
• Across the five-year window, Gross Profit sank 30.01% in 2023 and surged 102.72% in 2026, its largest moves.
• Year by year, Gross Profit stood at $2.4 million in 2022, then retreated by 12.37% to $2.1 million in 2023, then advanced by 0.38% to $2.1 million in 2024, then jumped by 42.49% to $3.0 million in 2025, then rose by 2.38% to $3.1 million in 2026.
• Per Business Quant data, the three most recent Gross Profit figures were $3.1 million in Q1 2026, $3.0 million in Q4 2025, and $3.9 million in Q3 2025.